This inventor holds 1 USPTO granted patent and 8 published patent applications. Top assignee: Risen (Suzhou) Pharma Tech Co., Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Dawei Chen - Innovator in CD73 Inhibitors
Introduction
Dawei Chen is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of CD73 inhibitors. His work focuses on innovative compounds that have the potential to treat various diseases, including cancer and immune-related disorders.
Latest Patents
Dawei Chen holds 1 patent for his invention titled "CD73 inhibitors and pharmaceutical uses thereof." This patent includes compounds that inhibit CD73, also known as ecto-5′-nucleotidase. The invention outlines the structure of these inhibitor compounds and their pharmaceutical applications for treating or preventing CD73-associated diseases.
Career Highlights
Chen is currently employed at Risen (Suzhou) Pharma Tech Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His expertise in the field has positioned him as a key player in the development of new therapeutic strategies.
Collaborations
Dawei Chen collaborates with notable colleagues, including Jiasheng Lu and Gang Chen. Their combined efforts contribute to the ongoing research and development of effective treatments in the pharmaceutical industry.
Conclusion
Dawei Chen's work in CD73 inhibitors represents a significant advancement in the treatment of serious health conditions. His innovative approach and dedication to research continue to impact the field of pharmaceuticals positively.